Acadia Pharmaceutica (ACAD)
$44.34 0.18 (0.40%)
19:59 EST ACAD Stock Quote Delayed 15 Minutes
Previous Close $44.34
Market Cap 5.53B
PE Ratio -21.32
Volume (Avg. Vol.) 1.35M
Day's Range 44.00 - 45.42
52-Week Range 14.01 - 53.70
Dividend & Yield N/A (N/A)
ACAD Stock Predictions, Articles, and Acadia Pharmaceutica News
- From InvestorPlace
- From the Web
Many of these biotech companies are beating the Nasdaq Biotech Index. With cutting-edge therapies, these are great names to buy.
Healthcare stocks recovered throughout 2018 but the recent correction in some big names is creating an entry point.
ACADIA Pharmaceuticals (ACAD) stock was down more than 6% on Monday as an investigation was launched to examine the efficacy of one of its drugs.
ACADIA Pharmaceuticals(ACAD) stock was falling hard today on a report with concerns about its Parkinson's drug Nuplazid.
These five biotech stocks are being hit particularly hard right now. Here's what investors should know about each of these stocks to sell.
Biotech's luck is changing as the trend looks to be upward and outward for the biotech stocks. These are the five to watch.
After a painful 2016, biotech stocks are recovering this year. What lies ahead? Let's look at 5 biotech ETFs to find out
2017 is likely to see quite a few mergers & acquisitions, and companies like BKS, NFLX and ACAD are all ripe for the M&A picking.
Acadia stock took a big leap on rumors that Pfizer (PFE) is interested in a buyout. But ACAD stock investors shouldn't get too excited yet.
The following stocks were the biggest movers and shakers in the Manufacturing sector today.
The Manufacturing sector saw plenty of trading activity today, including the following leaders and losers.
The following stocks were moving the Manufacturing sector today.
Could we see a President Hillary Clinton? According to most polls, that's the likeliest outcome for Nov. 8. Get your portfolio prepared with the 16 best stocks to buy ahead of another White House stint for the Clintons.
This week, the ratings of 19 Biotechnology stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Q4 is usually a winner for biotech stocks, but these stocks could deliver more than their fair share of wins during the coming three months.
The ratings of 32 Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Navellier RatingsPowered by Portfolio Grader